Pharmexa presents data from malaria vaccine on international vaccine conference

Pharmexa's abstract ”Pre-clinical Development of A Pre-erythrocytic P.
falciparum Malaria DNA Vaccine Based on Conserved Cytotoxic T Lymphocyte and
Helper T Lymphocyte Epitopes Delivered by an In Vivo Electroporation Device”
has been selected for an oral presentation on the international scientific
conference “Vaccine Congress” which takes place in Amsterdam from 7-9th
December 2007. 

At the conference, Pharmexa will present data on a unique new malaria vaccine
designed using the company's patented Epitope Identification System (EIS®) and
poly-epitope DNA vaccine technologies. The vaccine was developed with funding
support (approximately USD 3.5 mill.) from the Division of Microbiology and
Infectious Diseases (DMID), National Institutes of Health (NIH). The vaccine,
which will be delivered using the in vivo electroporation device developed by
Ichor Medical Systems, Inc. (San Diego), will be evaluated by DMID in a Phase 1
trial starting in the third quarter of 2008. 


Hørsholm, September 4, 2007


Jakob Schmidt
Chief Executive Officer


Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45
4516 2525 
Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45
4060 2558 


Note to editors: Pharmexa A/S is a leading company in the field of active
immunotherapy and vaccines for the treatment of cancer, serious chronic and
infectious diseases. Pharmexa's proprietary technology platforms are broadly
applicable, allowing the company to address critical targets in cancer and
chronic diseases, as well as serious infectious diseases such as HIV,
influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide
vaccine that has entered phase III trials in pancreatic cancer and phase II
trials in liver cancer, and HIV and hepatitis vaccines in phase I/II.
Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma and
Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs
approximately 105 people and is listed on the Copenhagen Stock Exchange under
the trading symbol PHARMX.